Revision History

1 revisions for "Your Genes Might Predict How Well Ozempic Works — But the Effect Is Smaller Than Headlines Suggest"

A major genome-wide study of nearly 28,000 GLP-1 drug users, published in Nature in April 2026, identified variants in the GLP1R and GIPR genes linked to modest differences in weight loss and side effects. But the genetic signal explains only a fraction of response variability — non-genetic factors like sex, drug type, dose, and treatment duration matter far more — raising questions about whether pharmacogenomic testing for obesity drugs is anywhere close to clinical readiness.